SDGR

Schrodinger Inc

Add to Watchlist

Advanced Chart

19.640

+0.1(0.512%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

19.975

Open

19.540

VWAP

19.62

Vol

520.13K

Mkt Cap

1.45B

Low

19.480

Amount

10.21M

EV/EBITDA(TTM)

Total Shares

72.68M

988.08M

EV/OCF(TTM)

35.94

P/S(TTM)

6.00

Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

73.23M

+22.97%

-0.605

-26.22%

86.91M

-1.6%

-0.242

-56%

49.97M

+41.61%

-0.730

+40.43%

Estimates Revision

The market is revising Downward the revenue expectations for Schrödinger, Inc. (SDGR) for FY2025, with the revenue forecasts being adjusted by -0.59% over the past three months. During the same period, the stock price has changed by -8.65%.

Revenue Estimates for FY2025

Revise Downward

-0.59%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-10.07%

In Past 3 Month

Stock Price

Go Down

-8.65%

In Past 3 Month

11 Analyst Rating

34.42% Upside

Wall Street analysts forecast SDGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SDGR is 26.40 USD with a low forecast of 19.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

4 Hold

0 Sell

Moderate Buy

34.42% Upside

Current: 19.640

Low

19.00

Averages

26.40

High

33.00

34.42% Upside

Current: 19.640

Low

19.00

Averages

26.40

High

33.00

Citi

Buy -> Neutral

downgrade

$35 -> $20

2025-08-14

Reason

Citi

Price Target

$35 -> $20

2025-08-14

downgrade

Buy -> Neutral

Reason

Citi downgraded Schrodinger to Neutral from Buy with a price target of $20, down from $35. The firm cites the recent developments in the company's internally developed drug pipeline as well as continued headwinds facing the biotech and pharma industries, the analyst tells investors in a research note. Citi adds that its positive stance was largely based on the three shots on goal the company had in its early stage Phase 1 assets to highlight how its drug development platform could discover novel targets that biopharma partners would be interested in, but to date, Schrodinger's recent updates have fallen short, raising concerns on the potential of the company's proprietary drug portfolio efforts.

Barclays

Overweight

initiated

$25

2025-08-14

Reason

Barclays

Price Target

$25

2025-08-14

initiated

Overweight

Reason

Barclays initiated coverage of Schrodinger with an Overweight rating and $25 price target. The firm sees two \"value-inflecting\" data readouts for the company Q4. Schrodinger will announce initial Phase 1 data for SGR- 2921 and for SGR-3515 in advanced solid tumors, the analyst tells investors in a research note.

Morgan Stanley

Sean Laaman

Equal Weight

downgrade

$31 -> $28

2025-07-03

Reason

Morgan Stanley

Sean Laaman

Price Target

$31 -> $28

2025-07-03

downgrade

Equal Weight

Reason

Morgan Stanley analyst Sean Laaman assumed coverage of Schrodinger with an Equal Weight rating with a price target of $28, down from $31. Schrodinger has faced volatility due to a combination of macroeconomic factors, underperformance on initial clinical results and uncertainty on valuation and revenue drivers, the analyst tells investors in a research note. Schrodinger's software business provides a steady stream of revenue that acts as a safety net for the stock, regardless of the outcomes of partnerships and the proprietary pipeline, the firm says.

Keybanc

Scott Schoenhaus

Buy

Maintains

$30 → $32

2025-04-16

Reason

Keybanc

Scott Schoenhaus

Price Target

$30 → $32

2025-04-16

Maintains

Buy

Reason

KeyBanc analyst Scott Schoenhaus raised the firm's price target on Schrodinger to $32 from $30 and keeps an Overweight rating on the shares. Into Q1 earnings, the firm believes the focus for the HCIT sector will be on legislative policies, healthcare system utilization, and macro concerns on a slowing economy paired with potentially higher inflation. While valuations in HCIT land remain discounted vs. healthcare more broadly, KeyBanc thinks investors should be focused on companies that can drive meet/beats over the next 12 months. Specifically, it sees the least risk from a revenue and earnings perspective from companies that are well positioned in the more stable healthcare end markets serving the payers and large pharma.

Piper Sandler

Joseph Catanzaro

Buy

Maintains

$50 → $45

2025-02-27

Reason

Piper Sandler

Joseph Catanzaro

Price Target

$50 → $45

2025-02-27

Maintains

Buy

Reason

Piper Sandler lowered the firm's price target on Schrodinger to $45 from $50 and keeps an Overweight rating on the shares following quarterly results. The firm notes Schrodinger reiterated that it expects to report initial clinical data from 3 programs in 2025. Specifically, it refined guidance for SGR-1505, now expecting to report data in Q2 2025.

Keybanc

Scott Schoenhaus

Buy

Maintains

$25 → $27

2025-01-24

Reason

Keybanc

Scott Schoenhaus

Price Target

$25 → $27

2025-01-24

Maintains

Buy

Reason

KeyBanc raised the firm's price target on Schrodinger to $27 from $25 and keeps an Overweight rating on the shares. The firm thinks a more premium valuation multiple is deserved given the company's recurring, high-margin revenue streams; combined with large internal pipeline opportunities.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Schrodinger Inc (SDGR.O) is -8.21, compared to its 5-year average forward P/E of -23.72. For a more detailed relative valuation and DCF analysis to assess Schrodinger Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-23.72

Current PE

-8.21

Overvalued PE

151.30

Undervalued PE

-198.75

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-21.09

Current EV/EBITDA

-7.04

Overvalued EV/EBITDA

4.86

Undervalued EV/EBITDA

-47.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

14.93

Current PS

5.34

Overvalued PS

26.63

Undervalued PS

3.22

Financials

Annual

Quarterly

FY2025Q2

YoY :

+15.69%

54.76M

Total Revenue

FY2025Q2

YoY :

+0.33%

-52.90M

Operating Profit

FY2025Q2

YoY :

-20.12%

-43.17M

Net Income after Tax

FY2025Q2

YoY :

-20.27%

-0.59

EPS - Diluted

FY2025Q2

YoY :

-4.04%

-52.51M

Free Cash Flow

FY2025Q2

YoY :

-27.84%

47.77

Gross Profit Margin - %

FY2025Q2

YoY :

-110.66%

10.24

FCF Margin - %

FY2025Q2

YoY :

-30.95%

-78.84

Net Margin - %

FY2025Q2

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 214.18% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

553.1K

USD

6-9

Months

97.1K

USD

0-12

Months

27.2K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

200.0K

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.1M

Volume

Months

6-9

1.3M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 214.18% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

553.1K

USD

6-9

Months

97.1K

USD

0-12

Months

27.2K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

SDGR News & Events

Events Timeline

2025-08-14 (ET)

2025-08-14

07:00:54

Schrodinger discontinues SGR-2921 clinical development program

2025-06-12 (ET)

2025-06-12

07:59:15

Schrodinger announces initial clinical data from SGR-1505 study

2025-05-29 (ET)

2025-05-29

08:04:18

Schrodinger appoints Mannix Aklian as chief commercial officer

News

4.0

08-18Benzinga

Insights from 4 Analyst Ratings on Schrodinger

6.0

08-18Benzinga

Morgan Stanley Keeps Equal-Weight Rating on Schrodinger, Reduces Price Target to $19

5.0

08-15Newsfilter

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

People Also Watch

Helix Energy Solutions Group Inc

Liberty Broadband Corp

Dime Community Bancshares Inc

FAQ

What is Schrodinger Inc (SDGR) stock price today?

The current price of SDGR is 19.64 USD — it has increased 0.51 % in the last trading day.

SDGR

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

SDGR News & Events

Events Timeline

News

People Also Watch

FAQ

What is Schrodinger Inc (SDGR) stock price today?

What is Schrodinger Inc (SDGR)'s business?

What is the price predicton of SDGR Stock?

What is Schrodinger Inc (SDGR)'s revenue for the last quarter?

What is Schrodinger Inc (SDGR)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Schrodinger Inc (SDGR)'s fundamentals?

How many employees does Schrodinger Inc (SDGR). have?

What is Schrodinger Inc (SDGR) market cap?